OpenSAFELY
Reports

Vaccine Coverage (Children): 2nd dose

Description
Report on COVID-19 vaccination coverage in England, for all patients aged 5-15 registered with practices that use TPP SystmOne software, focussing on second doses which are due (i.e. where first dose was recorded at least 14 weeks ago). UPDATE: we are no longer updating these reports on a regular basis. If you do rely on these reports and data releases in your own work, please get in touch at the email address below.
Contact
Get in touch and tell us how you use this report or new features you'd like to see: team@opensafely.org
First published
08 Jul 2022
Last released
29 Jun 2022
Links

OpenSAFELY COVID Vaccine coverage report: second doses for 5 to 15 year olds

OpenSAFELY is a new secure analytics platform for electronic patient records built on behalf of NHS England to deliver urgent academic and operational research during the pandemic.

Since December 2020 we have been reporting on COVID-19 vaccination coverage (for patients aged 16 and over) in England using data from 40% of general practices that use TPP electronic health record software. In September 2021, the COVID vaccination programme was extended to 12-15 year olds. The Living with Covid guidance was updated in February 2022 to advise that vaccines would be offered to children between the ages of 5 and 11 from Spring 2022. As such, we are now regularly reporting on vaccination coverage for children between the age of 5 and 15.

The data requires careful interpretation and there are a number of caveats, please refer to our peer-reviewed publications (https://doi.org/10.3399/BJGP.2021.0376) for further details. While this publication describes an analysis of vaccine uptake in those 16 and over, it is relevant here as the core functionality has been repurposed to generate our vaccine coverage reports for 5-15 year olds.

The full analytical methods behind the latest results in this report are available here.

Vaccines approved for use in children

The 30 microgram dose of the Pfizer BioNTech COVID-19 vaccine BNT162b2 was approved for use in 12-15 year olds in June 2021. In December 2021, the MHRA approved a 10 microgram dose for children aged 5-11 years. Where the paediatric formulation is not available, 10 micrograms (0.1ml) of the diluted adult vaccine may be used as an alternative. The Moderna vaccine has also been approved for use in 12-17 year olds.

More information regarding vaccines approved for use is available in The Green Book, chapter 14a, see specifically the "Vaccine Effectiveness" (p.6-7) and "Dosing and Schedule" (p. 12-13) sections.

Second doses

Second doses are recommended to occur within 8 weeks for children at high risk and within 12 weeks for all other children. In this report we consider an individual to be 'due' to receive their second dose if their first dose more than 14 weeks ago. Anyone who as not had their second dose by 14 weeks is described as 'overdue'.

Please note: This report is intended to highlight any differences between population subgroups in receiving second doses, only including those which are due (i.e. where at least 14 weeks has passed since the first dose) unless otherwise stated. It is therefore NOT a comprehensive view of all second doses given to date - to see these figures please refer to the main report.

Report last updated 28 Jun 2022

Second dose vaccinations included up to 22 Jun 2022 inclusive

Only 5-15 year olds who had their first dose between the start of the campaign (4th August 2021) and 7 weeks ago (16 Mar 2022) are included in the 'due' group.

Contents

Brand counts

Note that the total in this table may not be identical to that provided elsewhere and percentages may not sum to 100%. There are several aspects of the recorded data and analysis that impact on these totals:

  • It is not always possible to determine the vaccine type given; these patients are removed from the brand totals
  • Occasionally patients have more than one brand recorded on the same day; these patients are removed from the brand totals
  • We round to seven to mitigate against risk of disclosure; these totals are calculated from previously rounded numbers
  • Second doses are counted here whether they are 'due' or not
Second doses as at 22 Jun 2022 % second doses as at 22 Jun 2022
Group Vaccine brand
5-11 Pfizer (30 micrograms) 301 2.90
Pfizer (10 micrograms) 10066 97.03
Other 7 0.07
12-15 Pfizer (30 micrograms) 420511 99.72
Pfizer (10 micrograms) 1043 0.25
Other 147 0.03

Notes

  • Patient counts are rounded to nearest 7

  • 'Other' vaccines are Oxford-AZ or Moderna

  • For the brand totals, second doses given in these timescales are counted whether or not they were 'due' according to the relevant dosing schedule at the time.

Second dose coverage by first dose brand

The percentage of second doses received by first dose brand are provided below.

Note that these figures are raw proportions and do not take into account how many are due; this may vary substantially by brand.

Second doses (% of all vaccinated): 51.3% (432,082)

Second doses (% of Pfizer (30 micrograms) first doses): 66.6% (420,812)

Second doses (% of Pfizer (10 micrograms) first doses): 5.3% (11,109)

Second doses (% of Other (Oxford-AZ or Moderna) first doses): 35.0% (147)

Cumulative second dose vaccination figures among 5-11 population

Please refer to footnotes below table for information.

Second Doses due at 22 Jun 2022 (n) Second doses overdue (n) Second doses given (n) Second doses given (% of due) Total population
Category Group
overall overall 14,875 5,915 8,960 60.2 2,018,618
Sex F 6,076 2,324 3,752 61.8 983,283
M 8,799 3,598 5,201 59.1 1,035,321
Ethnicity (broad categories) Black 217 105 112 51.6 64,694
Mixed 441 168 273 61.9 77,252
Other 259 112 147 56.8 56,700
South Asian 847 336 511 60.3 193,025
Unknown 574 245 329 57.3 218,995
White 12,544 4,963 7,581 60.4 1,407,924
Ethnicity (detailed categories) African 154 70 84 54.5 42,007
Bangladeshi or British Bangladeshi 91 35 56 61.5 16,478
Caribbean 14 7 7 50.0 7,126
Chinese 77 42 35 45.5 10,570
Other 182 70 112 61.5 46,151
Other Asian 140 56 84 60.0 36,736
British or Mixed British 11,872 4,683 7,189 60.6 1,237,579
Indian or British Indian 350 119 231 66.0 63,637
Irish 21 7 14 66.7 3,892
Other Black 49 28 21 42.9 15,575
Other White 644 266 378 58.7 166,432
Other mixed 182 70 112 61.5 29,547
Pakistani or British Pakistani 266 119 147 55.3 76,167
Unknown 574 245 329 57.3 218,988
White + Asian 126 42 84 66.7 17,976
White + Black African 70 28 42 60.0 12,649
White + Black Caribbean 63 28 35 55.6 17,087
Index of Multiple Deprivation (quintiles) 1 Most deprived 2,590 1,190 1,400 54.1 482,552
2 2,646 1,106 1,540 58.2 392,119
3 3,045 1,162 1,883 61.8 379,827
4 2,968 1,141 1,827 61.6 350,350
5 Least deprived 2,968 1,078 1,890 63.7 329,126
Unknown 658 231 427 64.9 84,623
brand of first dose Other 14 14 0 0.0 56
Pfizer (10 micrograms) 14,245 5,586 8,659 60.8 195,825
Pfizer (30 micrograms) 504 252 252 50.0 1,421
Unknown 112 77 35 31.2 238

Footnotes:

  • Patient counts rounded to the nearest 7.
  • Only persons who are currently registered and had their first dose at least 14 weeks ago are included in the 'due' group.

Second Doses Overdue Among 5-11 Population

Second doses which have not been given at least 14 weeks since the first dose

Error bars indicate possible error caused by rounding

Cumulative second dose vaccination figures among 12-15 population

Please refer to footnotes below table for information.

Second Doses due at 22 Jun 2022 (n) Second doses overdue (n) Second doses given (n) Second doses given (% of due) Total population
Category Group
overall overall 597,051 177,856 419,195 70.2 1,177,694
Sex F 292,159 85,925 206,234 70.6 574,763
M 304,857 91,917 212,940 69.8 602,861
Ethnicity (broad categories) Black 11,228 5,306 5,922 52.7 40,677
Mixed 14,322 4,746 9,576 66.9 37,380
Other 12,684 4,130 8,554 67.4 32,074
South Asian 49,154 16,856 32,298 65.7 112,273
Unknown 43,918 12,656 31,262 71.2 92,393
White 465,717 134,169 331,548 71.2 862,827
Ethnicity (detailed categories) African 7,665 3,675 3,990 52.1 25,312
Bangladeshi or British Bangladeshi 4,564 1,897 2,667 58.4 9,870
Caribbean 854 378 476 55.7 4,725
Chinese 3,577 938 2,639 73.8 6,566
Other 9,100 3,185 5,915 65.0 25,501
Other Asian 10,661 3,780 6,881 64.5 22,708
British or Mixed British 432,474 123,473 309,001 71.4 759,689
Indian or British Indian 19,684 5,040 14,644 74.4 34,769
Irish 966 252 714 73.9 2,338
Other Black 2,709 1,246 1,463 54.0 10,640
Other White 32,277 10,437 21,840 67.7 100,814
Other mixed 5,607 1,792 3,815 68.0 14,329
Pakistani or British Pakistani 14,245 6,139 8,106 56.9 44,926
Unknown 43,904 12,642 31,262 71.2 92,386
White + Asian 4,228 1,169 3,059 72.4 8,477
White + Black African 2,268 910 1,358 59.9 6,559
White + Black Caribbean 2,226 875 1,351 60.7 8,022
Index of Multiple Deprivation (quintiles) 1 Most deprived 100,429 40,831 59,598 59.3 276,059
2 104,153 35,728 68,425 65.7 226,842
3 118,846 35,476 83,370 70.1 224,588
4 123,879 31,773 92,106 74.4 212,093
5 Least deprived 133,077 29,043 104,034 78.2 206,479
Unknown 16,632 4,991 11,641 70.0 31,570
brand of first dose Other 280 147 133 47.5 329
Pfizer (10 micrograms) 1,484 602 882 59.4 13,349
Pfizer (30 micrograms) 595,203 177,079 418,124 70.2 630,224
Unknown 49 21 28 57.1 70

Footnotes:

  • Patient counts rounded to the nearest 7.
  • Only persons who are currently registered and had their first dose at least 14 weeks ago are included in the 'due' group.

Second Doses Overdue Among 12-15 Population

Second doses which have not been given at least 14 weeks since the first dose

Error bars indicate possible error caused by rounding

Summary

Second Doses due at 22 Jun 2022 (n) Second doses given (% of due) Second doses given (n) Second doses overdue (n) Total population
5-11 14,875 60.2 8,960 5,915 2,018,618
12-15 597,051 70.2 419,195 177,856 1,177,694